The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry
Abstract
The liver is critical to consider during drug development because of its central role in the handling of xenobiotics, a process which often leads to localized and/or downstream tissue injury. Our ability to predict human clinical safety outcomes with animal testing is limited due to species differences in drug metabolism and disposition, while traditional human in vitro liver models often lack the necessary in vivo physiological fidelity. To address this, increasing numbers of liver microphysiological systems (MPS) are being developed, however the inconsistency in their optimization and characterization often leads to models that do not possess critical levels of baseline performance that is required for many pharmaceutical industry applications. Herein we provide a guidance on best approaches to benchmark liver MPS based on 3 stages of characterization that includes key performance metrics and a 20 compound safety test set. Additionally, we give an overview of frequently used liver injury safety assays, describe the ideal MPS model, and provide a perspective on currently best suited MPS contexts of use. This pharmaceutical industry guidance has been written to help MPS developers and end users identify what could be the most valuable models for safety risk assessment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These consortia not only promote MPS and OoC adoption but also generate lists of reference compounds relevant to various organ systems (Ainslie et al., 2019; Baudy et al., 2020; Hardwick et al., 2020; Peters et al., 2020; Phillips et al., 2020; Pointon et al., 2021).”
From Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip (2024) · cites this paper as Baudy et al., 2020
In the citing paper
“Guided by the IQ MPS affiliate’s roadmap on liver MPS19, which states that in vitro models for predicting drug-induced liver injury (DILI) that meet its guidelines are more likely to exhibit higher predictive validity than those that do not”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [19]
In the citing paper
“Albumin and urea production are widely accepted as functional markers for cultured hepatocytes with the goal of reaching computed production levels observed in human liver in vivo (~20–105 µg and 56–159 µg per 106 hepatocytes per day, respectively)19,26.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [19]
Citations
Cites
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Heroux, J., & Gharib, A. M. (2008) · Molecular Imaging in Oncology · doi:10.3109/9781420019957-3 · Cited by 2,187
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
R EGULATION OF E NZYMES OF THE U REA C YCLE AND A RGININE M ETABOLISM
Morris, S. M. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.110801.140547 · Cited by 725
Sitaxsentan Therapy for Pulmonary Arterial Hypertension
Barst, R. J., Langleben, D., Frost, A., Horn, E. M., Oudiz, R., Shapiro, S., McLaughlin, V., Hill, N., Tapson, V. F., Robbins, I. M., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200307-957oc · Cited by 706
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Research works printed but not linked: 15
- R. Becker , A.Chakravarty , D.Cho , O.Faris , S.Fitzpatrick , N.Hunter , I.Irony , S.Lababidi , C.Leptak , W.Mattes , E.Mishina , K.O'Callaghan , M.Pacanowski , E.Papadopoulos , V.Peiris , R.Puri , M.Robb , H.Rogers , R.Sherman , R.Sridhara , R.Temple , A.Trentacosti , P.Turfle , S.Wang , H.Hamilton , P.McInnes , L.McShane and M.Shah , BEST (Biomarkers, EndpointS, and other Tools) Resource , Silver Spring (MD) , 2018
- Kizawa, 2017, Biochem. Biophys. Rep., 10, 186
- Chen, 2013, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
- Hosey, 2016, AAPS J., 18, 251, 10.1208/s12248-015-9845-2 · DOI
- Shah, 2015, Toxicol. Sci., 147, 500, 10.1093/toxsci/kfv152 · DOI · Paper page
- Kock, 2014, Drug Metab. Dispos., 42, 665, 10.1124/dmd.113.054304 · DOI · Paper page
- Morgan, 2010, Toxicol. Sci., 118, 485, 10.1093/toxsci/kfq269 · DOI · Paper page
- Aleo, 2014, Hepatology, 60, 1015, 10.1002/hep.27206 · DOI · Paper page
- Proctor, 2017, Arch. Toxicol., 91, 2849, 10.1007/s00204-017-2002-1 · DOI · Paper page
- Bell, 2016, Sci. Rep., 6, 25187, 10.1038/srep25187 · DOI · Paper page
- Ballmer, 1990, Am. J. Physiol., 259, E797
- Hovens, 1994, Ned. Tijdschr. Geneeskd., 138, 363
- Prior, 2003, J. Psychiatry Neurosci., 28, 99
- Kostrubsky, 2000, Drug Metab. Dispos., 28, 1192
- Stork, 1997, J. Toxicol., 35, 105
Cited by
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337
The evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
Self-citation3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration
Wang, H., Brown, P. C., Chow, E. C. Y., Ewart, L., Ferguson, S. S., Fitzpatrick, S., Freedman, B. S., Guo, G. L., Hedrich, W., Heyward, S., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13066 · Cited by 212
“, metabolic clearance, RNA isolations, and lower sensitivity protein secretion assays), and (3) the ability to clearly image cell morphology using conventional laboratory systems.”
BackgroundSelf-citationStandardisation needs for organ on chip devices
Piergiovanni, M., Leite, S. B., Corvi, R., & Whelan, M. (2021) · Lab on a Chip · doi:10.1039/d1lc00241d · Cited by 155
Kim, J., Lee, C., Kim, I., Ro, J., Kim, J., Min, Y. H., Park, J., Sunkara, V., Park, Y.-S., Michael, I. J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c04778 · Cited by 126
Human biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
Fabre, K., Berridge, B., Proctor, W. R., Ralston, S., Will, Y., Baran, S. W., Yoder, G., & Van Vleet, T. R. (2020) · Lab on a Chip · doi:10.1039/c9lc01168d · Cited by 116
Self-citationPredictive validity in drug discovery: what it is, why it matters and how to improve it
Scannell, J. W., Bosley, J., Hickman, J. A., Dawson, G. R., Truebel, H., Ferreira, G. S., Richards, D. B., & Treherne, J. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00552-x · Cited by 142
Liver organ-on-chip models for toxicity studies and risk assessment
Messelmani, T., Morisseau, L., Sakai, Y., Legallais, C., Goff, A. L., Leclerc, É., & Jellali, R. (2022) · Lab on a Chip · doi:10.1039/d2lc00307d · Cited by 119
Rubiano, A., Indapurkar, A., Yokosawa, R., Miedzik, A., Rosenzweig, B. A., Arefin, A., Moulin, C., Dame, K., Hartman, N. R., Volpe, D. A., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12969 · Cited by 106
Towards in vitro models for reducing or replacing the use of animals in drug testing
Stresser, D. M., Kopec, A. K., Hewitt, P., Hardwick, R. N., Van Vleet, T. R., Mahalingaiah, P. K. S., O’Connell, D., Jenkins, G. J., David, R., Graham, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01154-7 · Cited by 94
Self-citationGeneration of human adult hepatocyte organoids with metabolic functions
Igarashi, R., Oda, M., Okada, R., Yano, T., Takahashi, S., Pastuhov, S., Matano, M., Masuda, N., Togasaki, K., Ohta, Y., et al. (2025) · Nature · doi:10.1038/s41586-025-08861-y · Cited by 85
“The hALB production rate in dHHO ranged from 50 to 150 μg day −1 per million cells, a value comparable to the estimated production rate in the human body (37–105 μg day −1 per million cells) 44 .”
The future of phenotypic drug discovery
Berg, E. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.01.010 · Cited by 74
Docci, L., Milani, N., Ramp, T., Romeo, A. A., Godoy, P., Franyuti, D. O., Krähenbühl, S., Gertz, M., Galetin, A., Parrott, N. J., et al. (2022) · Lab on a Chip · doi:10.1039/d1lc01161h · Cited by 74
Application of new approach methodologies for nonclinical safety assessment of drug candidates
Beilmann, M., Adkins, K., Boonen, H. C. M., Hewitt, P. G., Hu, W., Mader, R., Moore, S., Rana, P., Steger‐Hartmann, T., Villenave, R., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01182-9 · Cited by 85
Self-citationYouhanna, S. C., Kemas, A. M., Preiss, L. C., Zhou, Y., Shen, J. X., Cakal, S. D., Paqualini, F. S., Goparaju, S. K., Shafagh, R. Z., Lind, J. U., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000238 · Cited by 67
Ouédraogo, G., Alépée, N., Tan, B., & Roper, C. S. (2025) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2025.105904 · Cited by 64
Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development
Hargrove-Grimes, P., Low, L. A., & Tagle, D. A. (2021) · Cells Tissues Organs · doi:10.1159/000517422 · Cited by 62
“The IQ MPS Affiliate also stress the importance in development of animal MPS models of relevant preclinical species currently used in tox analyses (rat, dog, rhesus), which will help bolster end-user confidence in the fidelity of each platform [Baudy et al., 2020].”
BackgroundMethodInfluentialApplicability of organ-on-chip systems in toxicology and pharmacology
Schneider, M. R., Oelgeschläger, M., Burgdorf, T., van Meer, P. J. K., Theunissen, P. T., Kienhuis, A. S., Piersma, A. H., & Vandebriel, R. J. (2021) · Critical Reviews in Toxicology · doi:10.1080/10408444.2021.1953439 · Cited by 52
“Due to the early stage of MPS technologies, specific guidance on safety assessment by MPS models is not established at the level of regulatory bodies.”
BackgroundInfluential3D skin models along with skin-on-a-chip systems: A critical review
Sun, W., Liu, Z., Xu, J., Cheng, Y., Yin, R., Ma, L., Li, H., Qian, X. H., & Zhang, H. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.107819 · Cited by 47
Garcia, A. L. C., Arlt, V. M., & Phillips, D. H. (2021) · Mutagenesis · doi:10.1093/mutage/geab023 · Cited by 50
Organ-on-a-chip: current gaps and future directions
Candarlioglu, P. L., Negro, G. D., Hughes, D., Balkwill, F. R., Harris, K., Screen, H., Morgan, H., David, R., Beken, S., Guenat, O. T., et al. (2022) · Biochemical Society Transactions · doi:10.1042/bst20200661 · Cited by 50
Patient‐Derived Microphysiological Systems for Precision Medicine
Ko, J., Song, J., Choi, N., & Kim, H. N. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202303161 · Cited by 46
Sakolish, C., Reese, C. E., Luo, Y., Valdiviezo, A., Schurdak, M. E., Gough, A., Taylor, D. L., Chiu, W. A., Vernetti, L. A., & Rusyn, I. (2020) · Toxicology · doi:10.1016/j.tox.2020.152651 · Cited by 45
“2020), and in the lower range of human liver in vivo estimates (Baudy et al. 2020).”
BackgroundInfluentialOrgan-on-chip applications in drug discovery: an end user perspective
Clapp, N., Amour, A., Rowan, W. C., & Candarlioglu, P. L. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210840 · Cited by 47
Challenges and opportunities for human Organ Chips in FDA assessments and pharma pipelines
Ingber, D. E. (2026) · Cell stem cell · doi:10.1016/j.stem.2025.12.022 · Cited by 44
Kopec, A. K., Yokokawa, R., Khan, N., Horii, I., Finley, J. E., Bono, C. P., Donovan, C. B., Roy, J., Harney, J. A., Burdick, A. D., et al. (2021) · The Journal of Toxicological Sciences · doi:10.2131/jts.46.99 · Cited by 44
“Details on the recommended specifications for evaluating liver MPS models are discussed by Baudy and colleagues in their recent publication (Baudy et al., 2020).”
Fanizza, F., Boeri, L., Donnaloja, F., Perottoni, S., Forloni, G., Giordano, C., & Albani, D. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00346 · Cited by 38
Xiao, R., Lv, T., Tu, X., Li, P., Wang, T., Dong, H., Tu, P., & Ai, X. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27931 · Cited by 38
“The albumin secretion was less than a 50% change over a 28‐day period that met the requirement of the liver guidelines developed by members of IQ MPS Affiliate (Figure S3; Baudy et al., 2020).”
BackgroundMethodInfluentialEwart, L. C., Apostolou, A. P., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K., Joshipura, S. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472674 · Cited by 36
Rajan, S. A. P., Sherfey, J. S., Ohri, S., Nichols, L., Smith, J. T., Parekh, P., Kadar, E. P., Clark, F., George, B. T., Gregory, L., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00870-x · Cited by 37
“Tissue chips, or MPS, are generally engineered fluidic devices that uses a combination of human cells and biomaterials to better recapitulate the complexity of human physiology [7, 8].”
BackgroundInfluentialLiver-on-chips for drug discovery and development
Mehta, V., Karnam, G., & Madgula, V. L. M. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101143 · Cited by 59
“More-over, the stable expression of phase I and phase II metabolic enzymes and drug-relevant uptake and efflux transporters should be maintained and match the levels reported in freshly thawed hepatocytes [34,35].”
BackgroundMethodInfluentialJuguilon, C., Khosravi, R., Radisic, M., & Wu, J. C. (2025) · Circulation Research · doi:10.1161/circresaha.125.325497 · Cited by 47
Baker, T. K., Vleet, T. R. V., Mahalingaiah, P. K. S., Grandhi, T. S. P., Evers, R., Ekert, J. E., Gosset, J. R., Chacko, S. A., & Kopec, A. K. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001510 · Cited by 42
Organ-on-a-chip: current gaps and future directions.
Candarlioglu, P. L., Negro, G. D., Hughes, D. J., Balkwill, F. R., Harris, K., Screen, H. R. C., Morgan, H., David, R. M., Beken, S., Guenat, O. T., et al. (2022) · Open Access CRIS of the University of Bern · doi:10.48350/169390 · Cited by 34
Tomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., Candarlioglu, P. L., Chan, T. S., Chen, E., Choi, C. K., et al. (2024) · Advanced Biology · doi:10.1002/adbi.202300131 · Cited by 33
Self-citationShi, Q., Arefin, A., Ren, L., Papineau, K. S., Barnette, D. A., Schnackenberg, L. K., Hawes, J. J., Avigan, M., Mendrick, D. L., Ewart, L. C., et al. (2022) · Current Protocols · doi:10.1002/cpz1.478 · Cited by 34
Microphysiological systems in absorption, distribution, metabolism, and elimination sciences
Ness, K. P. V., Cesar, F., Yeung, C. K., Himmelfarb, J., & Kelly, E. J. (2021) · Clinical and Translational Science · doi:10.1111/cts.13132 · Cited by 40
Microphysiological systems: What it takes for community adoption
Hargrove-Grimes, P., Low, L. A., & Tagle, D. A. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211008872 · Cited by 35
Kang, W., Podtelezhnikov, A. A., Tanis, K. Q., Pacchione, S. J., Su, M., Bleicher, K. B., Wang, Z., Laws, G. M., Griffiths, T. G., Kuhls, M. C., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa094 · Cited by 29
Development of an AI model for DILI-level prediction using liver organoid brightfield images
Tan, S., Ding, Y., Wang, W., Rao, J., Cheng, F., Zhang, Q., Xu, T., Hu, T., Hu, Q., Ye, Z., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08205-6 · Cited by 26
“…analogs (troglitazone & pioglitazone, tolcapone & entacapone, nefazodone & buspirone, trova fl oxacin & levo fl oxacin), as well as 22 drugs knowntocoverknownDILImechanisms 22,23, (suchasmitochondrialinjury, reactive metabolites, biliary transport inhibition, and immune responses) for drug testing.”
Translating in vitro to in vivo and animal to human
Steger‐Hartmann, T., & Raschke, M. (2020) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2020.02.003 · Cited by 33
Nishikawa, M., Ito, H., Tokito, F., Hirono, K., Inamura, K., Scheidecker, B., Danoy, M., Kawanishi, T., Arakawa, H., Kato, Y., et al. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.810478 · Cited by 30
“Microphysiological systems (MPS), also known as organ-on-a-chip technology, have been proposed to recapitulate the in vivo physiological environment (Ribeiro et al., 2019; Baudy et al., 2020).”
BackgroundCox, B., Barton, P., Class, R., Coxhead, H., Delatour, C., Gillent, E., Henshall, J., Isin, E. M., King, L. M., & Valentin, J. (2022) · Biomaterials and Biosystems · doi:10.1016/j.bbiosy.2022.100054 · Cited by 34
Kato, Y., Lim, A. Y., Sakolish, C., Valdiviezo, A., Moyer, H. L., Hewitt, P. G., Bajaj, P., Han, G., & Rusyn, I. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105464 · Cited by 29
Self-citationWare, B. R., Liu, J. S., Monckton, C. P., Ballinger, K. R., & Khetani, S. R. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab018 · Cited by 25
Boul, M., Benzoubir, N., Messina, A., Ghasemi, R., Mosbah, I. B., Duclos‐Vallée, J., Dubart‐Kupperschmitt, A., & Pioufle, B. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-92011-7 · Cited by 27
Research and Development of Microphysiological Systems in Japan Supported by the AMED-MPS Project
Ishida, S. (2021) · Frontiers in Toxicology · doi:10.3389/ftox.2021.657765 · Cited by 29
“The discussions that took place within this forum have been summarized and published in several reviews within the last 2 years (Ainslie et al., 2019; Baudy et al., 2019; Fabre et al., 2019; Fowler et al., 2019; Hardwick et al., 2019; Philips et al., 2019).”
BackgroundKurniawan, D. A., Leo, S., Inamatsu, M., Funaoka, S., Aihara, T., Aiko, M. C., Rei, I., Sakura, T., Arakawa, H., Kato, Y., et al. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae070 · Cited by 25
“Despite this, the albu - min secretion value from MPS O 2 [+] was within the range of estimated albumin production in vivo (26).”
BackgroundYu, Y., Sun, B., Ye, X., Wang, Y., Zhao, M., Song, J., Geng, X., Marx, U., Li, B., & Zhou, X. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.115016 · Cited by 25
The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development
Zhou, Z., Zhu, J., Jiang, M., Sang, L., Hao, K., & He, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050704 · Cited by 23
Complex in vitro models positioned for impact to drug testing in pharma: a review
Kang, S., Chen, E. C., Cifuentes, H., Co, J. Y., Cole, G., Graham, J. C., Hsia, I., Kiyota, T., Klein, J. A., Kroll, K. T., et al. (2024) · Biofabrication · doi:10.1088/1758-5090/ad6933 · Cited by 24
“Efforts to harmonize functional assessments have led to the initiation of COU-independent guidelines based on basic biological features (e.g. albumin production, metabolic competence) [250].”
Valdiviezo, A., Brown, G. E., Michell, A. R., Trinconi, C. M., Bodke, V. V., Khetani, S. R., Luo, Y., Chiu, W. A., & Rusyn, I. (2022) · Environmental Health Perspectives · doi:10.1289/ehp12006 · Cited by 19
“2,17 – 30 Recent advancements in liver-based in vitro models, 31 including engineered human liver models, 32 – 34 have improved the capabilities of in vitro systems to mimic physiologically relevant metabolic function of the liver.”
Integrating Liver-Chip data into pharmaceutical decision-making processes
Levner, D., & Ewart, L. C. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2255127 · Cited by 20
Lim, A. Y., Kato, Y., Sakolish, C., Valdiviezo, A., Han, G., Bajaj, P., Stanko, J. P., Ferguson, S., Villenave, R., Hewitt, P. G., et al. (2023) · Bioengineering · doi:10.3390/bioengineering10101195 · Cited by 23
“Common benchmarks of the physiology of liver in vitro models include the level and sustainability in the production of albumin and urea and the activity of major metabolic enzymes [31].”
BackgroundMethodInfluentialSelf-citationHepaChip-MP – a twenty-four chamber microplate for a continuously perfused liver coculture model
Busche, M., Tomilova, O., Schütte, J., Werner, S., Beer, M., Groll, N., Hagmeyer, B., Pawlak, M., Jones, P. D., Schmees, C., et al. (2020) · Lab on a Chip · doi:10.1039/d0lc00357c · Cited by 19
Culturing the unculturables: strategies, challenges, and opportunities for gut microbiome study
Yadav, A., Ahlawat, S., & Sharma, K. K. (2023) · Journal of Applied Microbiology · doi:10.1093/jambio/lxad280 · Cited by 21
New approach methodologies (NAMs) for drug-induced liver injury (DILI): Where are we now?
Shrimali, S., Chen, M., Li, D., & Tong, W. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104452 · Cited by 19
Industry Adoption of Organoids and Organs‐on‐Chip Technology: Toward a Paradox of Choice
Homan, K. A. (2023) · Advanced Biology · doi:10.1002/adbi.202200334 · Cited by 22
Meneses, J., Conceição, F., van der Meer, A. D., de Wit, S., & Teixeira, L. M. (2024) · Frontiers in Lab on a Chip Technologies · doi:10.3389/frlct.2024.1376964 · Cited by 21
Moss, S. M., Schilp, J., Yaakov, M., Cook, M., Schuschke, E., Hanke, B., Strobel, H. A., & Hoying, J. B. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.06.003 · Cited by 16
Latest impact of engineered human liver platforms on drug development
Monckton, C. P., Brown, G. E., & Khetani, S. R. (2021) · APL Bioengineering · doi:10.1063/5.0051765 · Cited by 18
Organoids in drug development: from predictive models to regulatory integration
Song, X., Chen, X., Chen, Q., Wang, H., Zhang, T., Liao, M. Z., Liu, C., Yu, H., Hao, Y., Gu, G., et al. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104608 · Cited by 21
Weaver, J. R., Odanga, J. J., Wolf, K., Piekos, S. C., Biven, M., Taub, M. E., LaRocca, J. L., Thomas, C. T., Byer-Alcorace, A., Chen, J., et al. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105504 · Cited by 16
Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities
Maulana, T. I., Wevers, N. R., Kristoforus, T., Chandler, M. R., Lanz, H. L., Joore, J., Vulto, P., Villenave, R., Kustermann, S., Loskill, P., et al. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080621 · Cited by 24
Saydmohammed, M., Jha, A., Mahajan, V., Gavlock, D. C., Shun, T. Y., DeBiasio, R., Lefever, D. E., Li, X., Reese, C. E., Kershaw, E. E., et al. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211009228 · Cited by 20
A primary human Gut/Liver microphysiological system to estimate human oral bioavailability
Abbas, Y., van Wyk, M., Sze, H., Christophi, J., Spreen, A., Bliton, R. J., Boazak, E. M., & Kostrzewski, T. M. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100130 · Cited by 18
Kukla, D. A., Belair, D. G., & Stresser, D. M. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.124.001653 · Cited by 14
Ohri, S., Parekh, P., Nichols, L., Rajan, S. A. P., & Cirit, M. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.124.001497 · Cited by 16
“Healthy liver MPS produced an average albumin level per day ranging from ~20 e 50 m g/day/10 6 hepatocytes during the culture duration, which is within physiological levels (Baudy et al, 2020).”
Sakolish, C., Luo, Y., Valdiviezo, A., Vernetti, L. A., Rusyn, I., & Chiu, W. A. (2021) · Toxicology · doi:10.1016/j.tox.2021.152954 · Cited by 13
Evaluation of Metabolism of a Defined Pesticide Mixture through Multiple In Vitro Liver Models
Valdiviezo, A., Kato, Y., Baker, E. S., Chiu, W. A., & Rusyn, I. (2022) · Toxics · doi:10.3390/toxics10100566 · Cited by 15
“New approach methods including multicell-based models such as microphysiological systems of the liver can potentially overcome the limitations associated with cell suspensions and monolayer cultures [20,21].”
BackgroundMethodResultBai, H., Olson, K. N. P., Pan, M., Marshall, T., Singh, H., Ma, J., Gilbride, P., Yuan, Y., McCormack, J., Si, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202304332 · Cited by 11
Danoy, M., Tauran, Y., Poulain, S., Jellali, R., Bruce, J., Leduc, M., Gall, M. L., Koui, Y., Arakawa, H., Gilard, F., et al. (2021) · APL Bioengineering · doi:10.1063/5.0041227 · Cited by 14
“It is also important to note that the albumin production rate remains much lower than the in vivo estimation (35–105lg/day/ 106, Baudy et al., 2020).”
BackgroundShrimali, S., Li, D., Knox, B., Tong, W., & Ning, B. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100187 · Cited by 15
Cadavid, J. L., Li, N. T., & McGuigan, A. P. (2024) · Biophysics Reviews · doi:10.1063/5.0179125 · Cited by 12
Organ‐on‐Chip: The Future of Nutrition Research in a One Health World
Cassotta, M., Elexpuru-Zabaleta, M., Cano, S. S., Díaz, Y. A., Giampieri, F., Xiaobo, Z., Zhang, D., Grosso, G., & Battino, M. A. (2025) · Food Frontiers · doi:10.1002/fft2.70000 · Cited by 12
Beyond the hype and toward application: liver complex in vitro models in preclinical drug safety
Jadalannagari, S., & Ewart, L. C. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2328794 · Cited by 14
“…the liver that could be used to predict DILI, and ii) enhance understanding of the biological mechanisms that drive the pathophysiology, the pharmaceutical industry worked within the Innovation and Quality Consortia’s IQ MPS affiliate to produce a paper describing development of liver CIVMs [53].”
Reconstitution of human tissue barrier function for precision and personalized medicine
Kim, J., Yoon, T., Lee, S. W., Kim, P. J., & Kim, Y. (2024) · Lab on a Chip · doi:10.1039/d4lc00104d · Cited by 16
Sakolish, C., Tsai, H.-H. D., Lin, H.-C., Bajaj, P., Villenave, R., Ferguson, S. S., Stanko, J. P., Becker, R. A., Hewitt, P., Chiu, W. A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13030563 · Cited by 11
Self-citationGan, J., Bolon, B. N., Vleet, T. V., & Wood, C. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821044-4.00005-4 · Cited by 15
Self-citationWeener, H. J., Middelkamp, H. H. T., & Van der Meer, A. D. (2024) · Frontiers in Toxicology · doi:10.3389/ftox.2024.1513002 · Cited by 10
Romaldini, A., Spanò, R., Veronesi, M., Grimaldi, B., Bandiera, T., & Sabella, S. (2024) · Cells · doi:10.3390/cells13181542 · Cited by 13
“…types, their organization in a 3D structure, and the maintenance of hepatocellular functionality for at least 2 weeks are fundamental requirements [10]. cell types, their organization in a 3D structure, reflecting acute or repeated doses for 28 days is requested for testing toxicants (OECD Test…”
BackgroundHoriuchi, S., Kuroda, Y., Komizu, Y., & Ishida, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010055 · Cited by 10
“In drug discovery research, an assay system that can be evaluated stably for toxicity and efficacy is required [9,16].”
BackgroundYamazaki, D., & Ishida, S. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101047 · Cited by 11
Taylor, K., Ram, R., Ewart, L. C., Goldring, C. E., Russomanno, G., Aithal, G. P., Kostrzewski, T. M., Bauch, C., Wilkinson, J. M., Modi, S., et al. (2025) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2025.1536756 · Cited by 12
A scalable human liver-on-a-chip platform for predictive safety assessment
Kulkarni, G., Chen, L., Sang, J., Seo, J. H., Grall, R., Wang, Y., Gilbride, P., Yuan, Y., Albaum-Getzen, M., McCormack, J., et al. (2025) · Toxicology · doi:10.1016/j.tox.2025.154378 · Cited by 12
Gökçe, F., Kaestli, A. J., Lohasz, C., de Geus, M., Kaltenbach, H., Renggli, K., Bornhauser, B. C., Hierlemann, A. R., & Modena, M. M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202506 · Cited by 8
Development of a Perfusing Small Intestine–Liver Microphysiological System Device
Sakai, Y., Matsumura, M., Yamada, H., Doi, A., Saito, I., Iwao, T., & Matsunaga, T. (2023) · Applied Sciences · doi:10.3390/app131810510 · Cited by 11
“Liver MPS models are being developed to accurately predict metabolic abilities and toxicity during the drug discovery process [6].”
MethodLimitations of acetaminophen as a reference hepatotoxin for the evaluation of in vitro liver models
Livoti, L. A., Sison-Young, R. L. C., Reddyhoff, D., Fisher, C., Gardner, I. B., Díaz-Nieto, R., Goldring, C. E., & Copple, I. M. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae133 · Cited by 8
Zhou, Y., Zhong, Y., & Lauschke, V. M. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2461484 · Cited by 9
“…for the development of liver MPS recommends that a qualified model should produce >37 µg of albumin and >56 µg of urea per day per 1 million hepatocytes, with all markers remaining stable over a 14-day period and a coefficient of variation of less than 30% around the mean daily level [12].”
In vitro liver models for toxicological research
Fukunaga, I., & Takebe, T. (2025) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2025.101478 · Cited by 7
Tevonian, E. N., Kan, E. L., Maniar, K. K., Wang, A. J., Datta, A., Kamm, R. D., Lauffenburger, D. A., & Griffith, L. G. (2026) · Nature Communications · doi:10.1038/s41467-025-68031-6 · Cited by 14
“With these benchmarks of hepatic function meeting ranges in accordance with in vivo function 48 , we then investigated additional behaviors of the vascularized liver MPS in simulated disease conditions.”
Naz, D., Zeb, A., Nazir, N., Ullah, R., Rahman, A. U., & Muhammad, A. (2023) · 3 Biotech · doi:10.1007/s13205-023-03641-9 · Cited by 7
“The liver is a prone organ to higher doses and damages the cellular architecture of the liver in humans and animals (Baudy et al. 2020).”
BackgroundState of the Art in Integrated Biosensors for Organ-on-a-Chip Applications
Dey, T., Mitra, P., Chakraborty, B., Sanyal, A., Acharjee, A., Ghosh, A., & Mandal, D. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-99-6597-7_10 · Cited by 9
Opportunities for Biomanufacturing in Low Earth Orbit: Current Status and Future DirectionsPreprint
Giulianotti, M. A., Sharma, A., Clemens, R. A., Garcia, O., Taylor, L., Wagner, N. L., Shepard, K. A., Gupta, A., Malany, S., Grodzinsky, A. J., et al. (2021) · Preprints.org · doi:10.20944/preprints202108.0044.v1 · Cited by 7
Negi, C. K., Sakolish, C., Tsai, H.-H. D., Nitsche, K. S., Gang, H., Bajaj, P., Ferguson, S., Stanko, J. P., Hewitt, P. G., Kukla, D. A., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00554 · Cited by 7
Self-citationTechnical evaluation and standardization of the human thyroid microtissue assay
Foley, B. E., Hopperstad, K. A., Gamble, J. T., Lynn, S. G., Thomas, R. S., & Deisenroth, C. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae014 · Cited by 6
An All-Human Hepatic Culture System for Drug Development Applications
Odanga, J. J., Gianulis, E. C., Whaley, L., LeCluyse, E. L., Presnell, S. C., & Weaver, J. R. (2023) · Journal of Visualized Experiments · doi:10.3791/65992 · Cited by 8
Metadata
- Authors
- Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Springhouse (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Bristol-Myers Squibb (United States) (US)
- F. Hoffmann-La Roche AG (CH)
- Sanofi (United States) (US)
- AbbVie (United States) (US)
- AbbVie, Inc.
- Genentech (US)
- Corresponding author
- Baudy, Andreas R.
- ORCID
- Venue
- Lab on a Chip
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 20
- Issue
- 2
- Pages
- 215-225
- ISSN
- 1473-0189 (ISSN-L)
- 1473-0197
- OpenAlex
- W2990102938
- Cited by
- 150
- References
- 94
- Citations by year
- 2026: 22 · 2025: 27 · 2024: 22 · 2023: 20 · 2022: 23 · 2021: 27 · 2020: 9
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lab on a Chip (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- liver-on-a-chip, liver injury, hepatotoxicity, model characterization, model benchmarking, key performance indicators, in vitro liver models, drug metabolism, species differences in drug metabolism, drug development
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Pharmaceutical Preparations, Humans, Liver, Risk Assessment, Lab-On-A-Chip Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.